AlzeCure’s $12m payday fuels new brain-aging therapy

A Danish biotech’s $12 million payment for AlzeCure’s drug platform could reshape the treatment of Alzheimer’s and Parkinson’s. Small biotechs live and die by a brutal math problem: great science, not enough cash to prove it. AlzeCure Pharma, a Stockholm-listed company working on Alzheimer’s and pain, just solved that problem for at least one of […] The post AlzeCure’s $12m payday fuels new brain-aging therapy appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.